Pfizer Says Drug Tests Show Lower Abuse Potential Than Oxycodone – Wall Street Journal

May 1, 2014 8:38 a.m. ET

Pfizer Inc. on Thursday said tests indicate that its investigational pain drug has lower abuse potential than immediate-release oxycodone.

Additionally, the pharmaceutical giant said the ALO-02 investigational agent demonstrated in a Phase 3 study had a “statistically significant” difference in lower-back-pain scores compared to placebo.

“Chronic pain can have a profound negative impact on patients’ lives, and…

More:
(more…)

Pfizer Inc. Continues Development Program for RemoxyĀ® (oxycodone … – PharmiWeb.com…

Pfizer Inc. (NYSE: PFE) announced today that having achieved technical milestones related to manufacturing it will continue the development program for Remoxy® (oxycodone) Extended-Release Capsules CII. Following guidance received from the U.S. Food and Drug Administration (FDA) earlier this year Pfizer will proceed with the additional clinical studies and other actions required to address the Complete Response Letter received in June (more…)

Pfizer Inc. Continues Development Program for Remoxy® (oxycodone … – Business Wire…

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) announced today that, having achieved technical milestones related to manufacturing, it will continue the development program for Remoxy® (oxycodone) Extended-Release Capsules CII. Following guidance received from the U.S. Food and Drug Administration (FDA) earlier this year, Pfizer will proceed with the additional clinical studies and other actions required to address the Complete Response Letter received (more…)